F2G Biotech GmbH

🇦🇹Austria
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Phase 1
Completed
Conditions
Renal Impairment
Interventions
Drug: Olorofim
First Posted Date
2022-01-20
Last Posted Date
2023-01-20
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
16
Registration Number
NCT05200286
Locations
🇺🇸

Omega Research, Orlando, Florida, United States

Olorofim Aspergillus Infection Study

Phase 3
Recruiting
Conditions
Invasive Aspergillosis
Interventions
Drug: AmBisome®
Drug: Olorofim
First Posted Date
2021-11-01
Last Posted Date
2024-08-06
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
225
Registration Number
NCT05101187
Locations
🇧🇪

Hôpital Erasme, Bruxelles, Belgium

🇫🇷

Hospital Claude Huriez, Lille, Nord, France

🇪🇸

Hospital Universitari i Politecnic La Fe, Valencia, Spain

and more 137 locations

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: Olorofim
First Posted Date
2021-02-12
Last Posted Date
2022-03-16
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
32
Registration Number
NCT04752540
Locations
🇺🇸

Orange County Research Centre, Tustin, California, United States

🇺🇸

Orlando Clinical Research Centre, Orlando, Florida, United States

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Olorofim
First Posted Date
2019-12-23
Last Posted Date
2021-01-08
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
24
Registration Number
NCT04207957
Locations
🇬🇧

Covance Clinical Research Unit, Leeds, West Yorkshire, United Kingdom

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

First Posted Date
2019-11-21
Last Posted Date
2020-07-24
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
24
Registration Number
NCT04171739
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

Absorption, Metabolism and Excretion of 14C-olorofim in Man

Phase 1
Completed
Conditions
Invasive Fungal Infections
Interventions
Drug: Olorofim
First Posted Date
2019-07-31
Last Posted Date
2019-11-13
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
12
Registration Number
NCT04039880
Locations
🇳🇱

PRA Health Sciences, Groningen, Netherlands

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Phase 2
Completed
Conditions
Invasive Fungal Infections
Interventions
Drug: Olorofim
First Posted Date
2018-07-11
Last Posted Date
2024-07-10
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
203
Registration Number
NCT03583164
Locations
🇺🇸

UC Davis Medical Center, Sacramento, California, United States

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

🇦🇺

Peter MacCallum Centre-East Melbourne, Melbourne, Victoria, Australia

and more 79 locations

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

Phase 1
Completed
Conditions
Invasive Aspergillosis
Interventions
Drug: F901318
First Posted Date
2017-11-13
Last Posted Date
2018-08-02
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
45
Registration Number
NCT03340597
Locations
🇬🇧

Covance Clinical Research Unit, Leeds, West Yorkshire, United Kingdom

Drug/Drug Interactions With F901318

First Posted Date
2017-03-29
Last Posted Date
2017-11-01
Lead Sponsor
F2G Biotech GmbH
Registration Number
NCT03095547

Pharmacokinetics of IV Formulation

Phase 1
Withdrawn
Conditions
Invasive Aspergillosis
Interventions
Drug: F901318
First Posted Date
2017-03-10
Last Posted Date
2017-11-01
Lead Sponsor
F2G Biotech GmbH
Registration Number
NCT03076905
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy